Medicinal strategies in the treatment of obesity (original) (raw)

• World Health Organization. Obesity: Preventing and Managing the Global Epidemic. (World Health Organization, Geneva, 1998).
• National Heart Lung and Blood Institute. Clinical guidelines on the identification evaluation and treatment of overweight and obesity in adults — the evidence report. Obes. Res. 6 (Suppl. 2), 51S–290S ( 1998).
• Allison D. B. et al. Annual deaths attributable to obesity in the United States . J. Am. Med. Assoc. 282, 1530– 1538 (1999).
  Article CAS Google Scholar
• Bray, G. A. Drug treatment of obesity. Don't throw out the baby with the bath water. Am. J. Clin. Nutr. 67, 1–2 (1998).
  Article CAS PubMed Google Scholar
• Bray, G. A. Current and Contemporary Management of Obesity (Handbooks in Health Care, Newtown, PA, 1998).
  Google Scholar
• Bray, G. A. & Greenway, F. L. A review of current and potential drugs for treatment of obesity. Endocr. Rev. 20, 805–875 (1999).
  Article CAS PubMed Google Scholar
• Jequier, E. & Tappy, L. Regulation of body weight in humans . Physiol. Rev. 79, 451– 480 (1999).
  Article CAS PubMed Google Scholar
• Rolls, B. J., Shide, D. J., Thorwart, M. L. & Ulbrecht, J. S. Sibutramine reduces food intake in non-dieting women with obesity. Obes. Res. 6, 1–11 ( 1998).
  Article CAS PubMed Google Scholar
• Hansen, D. L. et al. Thermogenic effects of sibutramine in humans. Am. J. Clin. Nutr. 68, 1180–1186 (1998).
  Article CAS PubMed Google Scholar
• Seagle, H. M., Gessesen, D. H. & Hill, J. O. Effects of sibutramine on resting metabolic rate and weight loss in overweight women. Obes. Res. 6, 115–121 (1998).
  Article CAS PubMed Google Scholar
• Bray, G. A. et al. Sibutramine produces dose-related weight loss. Obes. Res. 7, 189–198 ( 1999).
  Article CAS PubMed Google Scholar
• Apfelbaum, M. et al. Long-term maintenance of weight loss after a very low calorie diet: efficacy and tolerability of sibutramine. Am. J. Med. 106, 179–184 (1999).
  Article CAS PubMed Google Scholar
• Guercolini, R. Mode of action of orlistat. Int. J. Obes. Relat. Metab. Disord . 21, S12–S23 ( 1997).
  Google Scholar
• Hauptman, J. B., Jeunet, F. S. & Hartmann, D. Initial studies in humans with the novel gastrointestinal lipase inhibitor Ro 18-0647 (tetrahydrolipstatin). Am. J. Clin. Nutr. 55, 309S–313S ( 1992).
  Article CAS PubMed Google Scholar
• Sjostrom, L. et al. Randomized placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 352, 167– 172 (1998).
  Article CAS PubMed Google Scholar
• Davidson, M. H., Hauptman, J. & DiGirolamo, M. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat. A randomized controlled trial. J. Am. Med. Assoc. 281, 235–242 (1999).
  Article CAS Google Scholar
• Hollander, P. et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. Diabetes Care 21, 1288– 1294 (1998).
  Article CAS PubMed Google Scholar
• Hill, J. O. et al. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting — A 1 year study. Am. J. Clin. Nutr. 9, 1108–1116 ( 1999).
  Article Google Scholar
• Conavatchel, W. Long-term tolerability profile of orlistat, an intestinal lipase inhibitor . Diabetologia 40, A196 ( 1997).
  Google Scholar
• Astrup, A., Lundsgaard, C., Madsen, J., & Christensen, N. J. Enhanced thermogenic responsiveness during chronic ephedrine treatment in man. Am. J. Clin. Nutr. 42, 83– 94 (1985).
  Article CAS PubMed Google Scholar
• Astrup, A., Breum, L., Toubro, S., Hein, P. & Quaade, F. The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy-restricted diet. A double-blind trial. Int. J. Obes. Relat. Metab. Disord. 16, 269–277 ( 1992).
  CAS PubMed Google Scholar
• Toubro, S., Astrup, L., Breum, L. & Quaade, F. The acute and chronic effects of ephedrine/caffeine mixtures on energy expenditure and glucose metabolism in humans. Int. J. Obes. Relat. Metab. Disord. 17, S73–S77 (1993).
  PubMed Google Scholar
• Astrup, A. et al. The effect of ephedrine/caffeine mixture on energy expenditure and body composition in obese women. Metabolism 41, 686–688 (1992).
  Article CAS PubMed Google Scholar
• Zhang, Y. et al. Positional cloning of the mouse obese gene and its human homologue . Nature 372, 425–432 (1994).
  Article ADS CAS PubMed Google Scholar
• Tartaglia, L. A. et al. Identification and expression cloning of a leptin receptor OB-R. Cell 83, 1263–1271 (1995).
  Article CAS PubMed Google Scholar
• Chen, H. et al. Evidence that the diabetes gene encodes the leptin receptor: identification of a mutation in the leptin receptor gene in db/db mice. Cell 84, 491–495 ( 1996).
  Article CAS PubMed Google Scholar
• Lee, G. H. et al. Abnormal splicing of the leptin receptor in diabetic mice . Nature 379, 632–635 (1996).
  Article ADS CAS PubMed Google Scholar
• Chua, S. C. Jr et al. Phenotypes of mouse diabetes and rat fat due to mutations in the OB (leptin) receptor. Science 271, 994–996 (1996).
  Article ADS CAS PubMed Google Scholar
• Huszar, D. et al. Targeted disruption of the melanocortin-4 receptor results in obesity in mice. Cell 88, 131– 141 (1997).
  Article CAS PubMed Google Scholar
• Smith, G. P. Satiation: From Gut to Brain 291 (Oxford Univ. Press, New York, 1998).
  Book Google Scholar
• Gutzwiller J. P. et al. Effect of intravenous human gastrin-releasing peptide on food intake in humans. Gastroenterology 106, 1168–1173 (1994).
  Article CAS PubMed Google Scholar
• Flint, A., Raben, A. l., Astrup, A. & Holst, J. J. Glucagon-like peptide I promotes satiety and suppresses energy intake in humans. J. Clin. Invest. 101, 515–520 (1998).
  Article CAS PubMed PubMed Central Google Scholar
• Holst, J. J. Glucagon-like peptide-1 (GLP-1) — an intestinal hormone, signaling nutritional abundance, with an unusual therapeutic potential. Trends Endocrinol. Metab. 10, 229–235 ( 1999).
  Article CAS PubMed Google Scholar
• Gutzwiller, J. P. et al. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am. J. Physiol. 276 (5 Pt 2), R1541–R1544 (1999).
  CAS PubMed Google Scholar
• Erlanson-Albertsson, C. & York, D. Enterostatin – a peptide regulating fat intake. Obes. Res. 5, 360–372 (1997).
  Article CAS PubMed Google Scholar
• Smeets, M., Geiselman, P., Bray, G. A. & York, D. A. The effect of oral enterostatin on hunger and food intake in human volunteers . FASEB J. 13, A871 ( 1999).
  Google Scholar
• Wetherford, S. C. et al. Intraventricular administration of enterostatin decreases food intake in baboons. Appetite 19, 225 (1992).
  Article Google Scholar
• Morley, J. E., Flood, J. F., Horowitz, M., Morley, P. M. & Walter, M. J. Modulation of food intake by peripherally administered amylin. Am. J. Physiol. 276 (1 Pt 2), R178–R184 (1994 ).
  Google Scholar
• Nagase, H., Bray, G. A. & York, D. A. Effects of pyruvate and lactate on food intake in rat strains sensitive and resistant to dietary obesity. Physiol. Behav. 59, 555–560 ( 1996).
  Article CAS PubMed Google Scholar
• Scharrer, E. Control of food intake by fatty acid oxidation and ketogenesis. Nutrition 15, 704–714 ( 1999).
  Article CAS PubMed Google Scholar
• Sullivan, A. C., Triscari, J., Hamilton, J. G. & Miller, O. N. Effect of (–)-hydroxycitrate upon the accumulation of lipid in the rat. II. Appetite. Lipids 9, 129– 134 (1974).
  Article CAS PubMed Google Scholar
• Heymsfield, S. B. et al. Garcinia cambogia (hydroxycitric acid) as a potential antiobesity agent: a randomized controlled trial. J. Am. Med. Assoc. 280, 1596–1600 (1998).
  Article CAS Google Scholar
• Gietzen, D. W., Erecius, L. F. & Rogers, Q. R. Neurochemical changes after imbalanced diets suggest a brain circuit mediating anorectic responses to amino acid deficiency in rats. J. Nutr. 128, 771– 781 (1998).
  Article CAS PubMed Google Scholar
• Tso, P., Liu, M., & Kalogeris, T. J. The role of apolipoprotein A-IV in food intake regulation . J. Nutr. 8,1503–1506 (1999).
  Article Google Scholar
• Mantzoros, C. S. The role of leptin in human obesity and disease — a review of current evidence. Ann. Intern. Med. 130, 671– 680 (1999).
  Article CAS PubMed Google Scholar
• Cone, R. D. The central melanocortin system and energy homeostasis. Trends Endocrinol. Metab. 10, 211–216 (1999).
  Article CAS PubMed Google Scholar
• Wilson, B. D., Ollmann, M. M. & Barsh, G. S. The role of agouti-related protein in regulating body-weight. Mol. Med. Today 5, 250– 256 (1999).
  Article CAS PubMed Google Scholar
• Kristensen, P. et al. Hypothalamic CART is a new anorectic peptide regulated by leptin. Nature 393, 72– 76 (1998).
  Article ADS CAS PubMed Google Scholar
• Heymsfield, S. B. et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation study. J. Am. Med. Assoc. 282, 1568–1575.
• Farooqi, I. S. et al. Effects of recombinant leptin therapy in a child with congenital leptin deficiency. N. Engl. J. Med. 341, 879–884 (1999).
  Article CAS PubMed Google Scholar
• Ogawa, Y. et al. Increased glucose metabolism and insulin sensitivity in transgenic skinny mice overexpressing leptin. Diabetes 48, 1822–1829 (1999).
  Article CAS PubMed Google Scholar
• Bjorbaek, C. et al. Activation of SOCS-3 messenger ribonucleic acid in the hypothalamus by ciliary neurotrophic factor. Endocrinology 140, 2035–2043 (1999).
  Article CAS PubMed Google Scholar
• Zimanyi, I. A., Fathi, Z. & Poindexter, G. S. Central control of feeding behavior by neuropeptide Y. Curr. Pharm. Des. 4, 349– 366 (1998).
  CAS PubMed Google Scholar
• Palmiter, R. D. et al. in Pennington Center Nutrition Series: Nutrition, Genetics, and Obesity 269–286 (Louisiana State Univ. Press, Baton Rouge, 1999).
  Google Scholar
• Yaswen, L., Diehl, N., Brennan, M. B. & Hochgeschwender, U. Obesity in the mouse model of pro-opiomelanocortin deficiency responds to peripheral melanocortin. Nature Med. 5, 1066–1070 (1999).
  Article CAS PubMed Google Scholar
• Chambers, J. et al. Melanin-concentrating hormone is the cognate ligand for the orphan G-protein-coupled receptor SLC-1. Nature 400 , 261–269 (1999).
  Article ADS CAS PubMed Google Scholar
• Saito, Y. et al. Molecular characterization of the melanin-concentrating-hormone receptor. Nature 400, 265– 269 (1999).
  Article ADS CAS PubMed Google Scholar
• Shimada, M. et al. Mice lacking melanin-concentrating hormone are hypophagic and lean. Nature 396, 670– 673 (1998).
  Article ADS CAS PubMed Google Scholar
• Lembo, P. M. et al. The receptor for the orexigenic peptide melanin-concentrating hormone is a G-protein-coupled receptor. Nature Cell Biol. 5, 267–271 (1999).
  Article CAS Google Scholar
• Barton, C., York, D. A. & Bray, G. A. Opioid receptor subtype control of galinin-induced feeding . Peptides 17, 237–240 (1996).
  Article CAS PubMed Google Scholar
• Rokaeus, A., Jiang, K., Spyrou, G. & Waschek, J. A. Transcriptional control of the galanin gene. Tissue-specific expression and induction by NGF, protein kinase C, and estrogen. Ann. NY Acad. Sci. 863, 1–13 (1998).
  Article ADS CAS PubMed Google Scholar
• Sakurai, T. et al. Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92, 573–585 ( 1998).
  Article CAS PubMed Google Scholar
• Lin, L. et al. The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (Orexin) Receptor 2 gene. Cell 98, 365–376 (1999).
  Article CAS PubMed Google Scholar
• Chemelli, R. M. et al. Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation. Cell 98, 437– 451 (1999).
  Article CAS PubMed Google Scholar
• Kalra, S. P. et al. Interacting appetite-regulating pathways in the hypothalamic regulation of body weight. Endocr. Rev. 1, 68–100 (1999).
  Article Google Scholar
• Karolyi, I. J. et al. Altered anxiety and weight gain in corticotropin-releasing-hormone-binding protein-deficient mice. Proc. Natl Acad. Sci. USA 96 , 11595–11600 (1999).
  Article ADS CAS PubMed PubMed Central Google Scholar
• Vickers, S. P., Clifton, P. G., Dourish, C. T. & Tecott, L. H. Reduced satiating effect of d-fenfluramine in serotonin 5-HT (2C) receptor mutant mice. Psychopharmacology 143, 309 –314 (1999).
  Article CAS PubMed Google Scholar
• Smith, B. K., York, D. A. & Bray, G. A. Activation of hypothalamic serotonin receptors reduced intake of dietary fat and protein but not carbohydrate. Am. J. Physiol. 277, R802–R811 (1999).
  CAS PubMed Google Scholar
• Connolly, H. M. et al. Valvular heart disease associated with fenfluramine-phentermine . N. Engl. J. Med. 337, 581– 588 (1997).
  Article CAS PubMed Google Scholar
• Ryan, D. H. et al. Serial echocardiographic and clinical evaluation of valvular regurgitation before, during, and after treatment with fenfluramine or dexfenfluramine and mazindol or phentermine. Obes. Res. 7, 313–322 (1999).
  Article CAS PubMed Google Scholar
• Rothman, R. B., Ayestas, M. A., Dersch, C. M., & Baumann, M. H. Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates. Implications for primary pulmonary hypertension. Circulation 100, 869–875 (1999).
  Article CAS PubMed Google Scholar
• Heinonen, P. et al. Identification of a three-amino acid deletion in the alpha2B-adrenergic receptor that is associated with reduced basal metabolic rate in obese subjects . J. Clin. Endocrinol. Metab. 84, 2429– 2433 (1999).
  CAS PubMed Google Scholar
• Terry, P., Gilbert, D. B. & Cooper, S. J. Dopamine receptor subtype agonists and feeding behavior . Obes. Res. 3, 515S ( 1995).
  Article CAS PubMed Google Scholar
• Sakata, S., Yoshimatsu, H. & Kurokawa, M. Hypothalamic neuronal histamine: implications of its homeostatic control of energy metabolism. Nutrition 13, 403–411 (1997).
  Article CAS PubMed Google Scholar
• Lovenberg, T. W. et al. Cloning and functional expression of the human histamine H3 receptor. Mol. Pharmacol. 55, 1101– 1107 (1999).
  Article CAS PubMed Google Scholar
• Kurose, Y. & Terashima, Y. Histamine regulates food intake through modulating noradrenaline release in the para-ventricular nucleus. Brain Res. 15, 115–118 ( 1999).
  Article Google Scholar
• Stahl, A. et al. Identification of the major intestinal fatty acid transport protein . Mol. Cell 4, 299–308 (1999).
  Article CAS PubMed Google Scholar
• Bray, G. A. The Obese Patient (Saunders, Philadelphia, 1976).
  Google Scholar
• Danforth, E. Jr & Himms-Hagen, J. H. Obesity and diabetes and the beta-3 adrenergic receptor. Eur. J. Endocrinol. 136, 362–365 ( 1997).
  Article CAS PubMed Google Scholar
• Klingenberg, M. & Huang, S. G. Structure and function of the uncoupling protein from brown adipose tissue. Biochim. Biophys. Acta 8, 271–296 (1999).
  Article Google Scholar
• Fleury, C. et al. Uncoupling protein-2: a novel gene linked to obesity and hyperinsulinemia . Nature Genet. 15, 269– 272 (1997).
  Article CAS PubMed Google Scholar
• Gimeno, R. E. et al. Cloning and characterization of an uncoupling protein homolog: a potential molecular mediator of human thermogenesis. Diabetes 46, 900–906 ( 1997).
  Article CAS PubMed Google Scholar
• Vidal-Puig, A., Solanes, G., Grujic, D., Flier, J. S. & Lowell, B. B. UCP3: an uncoupling protein homologue expressed preferentially and abundantly in skeletal muscle and brown adipose tissue. Biochem. Biophys. Res. Commun. 235, 79–82 (1997).
  Article CAS PubMed Google Scholar
• Boss, O. et al. Uncoupling protein-3: a new member of the mitochondrial carrier family with tissue-specific expression. FEBS Lett. 408, 39–42 (1997).
  Article ADS CAS PubMed Google Scholar
• Gong, D. W., He, Y., Karas, M. & Reitman, M. Uncoupling protein-3 is a mediator of thermogenesis regulated by thyroid hormone, beta3-adrenergic agonists, and leptin. J. Biol. Chem. 39, 24129–24132 (1997).
  Article Google Scholar
• Elchebly, M. et al. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science 283, 1544–1548 (1999).
  Article ADS CAS PubMed Google Scholar
• Cases, S. et al. Identification of a gene encoding an acyl CoA: diacylglycerol acyltransferase, a key enzyme in triacyglycerol synthesis. Proc. Natl Acad. Sci. USA 95, 13018–13023 (1998).
  Article ADS CAS PubMed PubMed Central Google Scholar
• Marin, P. et al. Androgen treatment of abdominally obese men. Obes. Res. 1, 245–251 ( 1993).
  Article ADS CAS PubMed Google Scholar
• Marin, P. et al. The effects of testosterone on body composition and metabolism in middle-aged obese men. Int. J. Obes. Relat. Metab. Disord. 16, 991–997 (1992).
  CAS PubMed Google Scholar
• Lovejoy, J. C. et al. Oral anabolic steroid treatment, but not parenteral androgen treatment, decreases abdominal fat in obese, older men. Int. J. Obes. Relat. Metab. Disord. 19, 614– 624 (1995).
  CAS PubMed Google Scholar
• Kin, K. R. et al. Low-dose growth hormone treatment with diet restriction accelerates body fat loss, exerts anabolic effect and improves growth hormone secretory dysfunction in obese adults. Hormone Res. 51, 78–84 (1999).
  Article ADS Google Scholar
• Bujalska, I. J., Kumar, S., Hewison, M. & Stewart, P. M. Differentiation of adipose stromal cells: the roles of glucocorticoids and 11 beta-hydroxysteroid dehydrogenase. Endocrinology 140, 3188– 3196 (1999).
  Article CAS PubMed Google Scholar
• Greenway, F. L. & Bray, G. A. Topical fat reduction . Obes. Res. 3 (Suppl. 4), 561S –568S (1995).
  Article CAS PubMed Google Scholar